Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for iTeos Therapeutics, Inc. (ITOS : NSDQ)

• Company Description    iTeos Therapeutics Inc. is a clinical-stage biopharmaceutical company. It engages in the discovery and development of immuno-oncology therapeutics. iTeos Therapeutics Inc. is based in Cambridge, United States. Number of Employees: 173

• Price / Volume Information    Yesterday's Closing Price: $10.21 Daily Weekly Monthly 20 Day Moving Average: 715,336 shares Shares Outstanding: 38.27 (millions) Market Capitalization: $390.77 (millions) Beta: 1.49 52 Week High: $18.13 52 Week Low: $4.80 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 2.30% -1.53% 12 Week 56.84% 31.92% Year To Date 32.94% 24.50%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 321 ARSENAL STREET BLDG 312 FLOOR 3 SUITE 301 - WATERTOWN,MA 02472 USA ph: 339-217-0162 fax: - ir@iteostherapeutics.com http://www.iteostherapeutics.com

• General Corporate Information    Officers Michel Detheux - President; Chief Executive Officer and Director David L. Hallal - Chairman of the Board of Directors and Director Matthew Gall - Chief Financial Officer Jill M. DeSimone - Director Robert Iannone - Director Peer Information iTeos Therapeutics, Inc. (CORR.) iTeos Therapeutics, Inc. (RSPI) iTeos Therapeutics, Inc. (CGXP) iTeos Therapeutics, Inc. (BGEN) iTeos Therapeutics, Inc. (GTBP) iTeos Therapeutics, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 46565G104 SIC: 2836 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/25 Next Expected EPS Date: 08/14/25 Share - Related Items Shares Outstanding: 38.27 Most Recent Split Date: (:1) Beta: 1.49 Market Capitalization: $390.77 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.68 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-2.80 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 4.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/14/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 0.69 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 25.23% vs. Previous Quarter: 20.79% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 06/30/25 - - 03/31/25 - -21.37 12/31/24 - -22.16 ROA 06/30/25 - - 03/31/25 - -18.55 12/31/24 - -19.26 Current Ratio 06/30/25 - - 03/31/25 - 14.13 12/31/24 - 12.62 Quick Ratio 06/30/25 - - 03/31/25 - 14.13 12/31/24 - 12.62 Operating Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Net Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Pre-Tax Margin 06/30/25 - - 03/31/25 - -336.72 12/31/24 - -343.83 Book Value 06/30/25 - - 03/31/25 - 14.72 12/31/24 - 16.16 Inventory Turnover 06/30/25 - - 03/31/25 - - 12/31/24 - - Debt-to-Equity 06/30/25 - - 03/31/25 - 0.00 12/31/24 - 0.00 Debt-to-Capital 06/30/25 - - 03/31/25 - 0.00 12/31/24 - 0.00

Powered by Zacks Investment Research ©